8. Diagnosis or treatment for another systemic malignancy within 2 years before study treatment initiation, or who had received a diagnosis of another malignancy before that and have evidence of residual disease. Patients with non-melanoma skin cancer or carncinoma in situ who have undergone complete resection will not be excluded from the study.